Monoclonal gammopathy of unknown significance (MGUS) & importance of regularly monitoring patients

Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses monoclonal gammopathy of unknown significance (MGUS). There are still questions around how to follow up patients with MGUS and whether these patients should be followed up regularly or not. Watch video here.

Dana-Farber Cancer Institute logo
Center for Prevention of Progression of Blood Cancers

© 2018 Dana-Farber Cancer Institute |  Terms of Use  |   Privacy Policy